In the phase 3 LUNA trial, atogepant demonstrated a significant reduction in migraine days during the perimenstrual period compared with placebo.

Phase 3 Emerge trial results show a single 100µg dose of lysergide ODT produced rapid, statistically significant, and durable improvements in depression scores through 12 weeks.

HealthDay News — From 2019 to 2026, there was an increase in glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescribing for children aged 8 to 11 years without diabetes but with obesity, ...

B-cell-depleting therapy linked to lower relapse incidence, greater T2 lesion volume reduction compared with oral platform therapies ...

FDA grants Fast Track designation to pacritinib for VEXAS syndrome, providing a potential therapeutic option for a severe hemato-inflammatory condition with no current approved treatments.

The FDA has granted Priority Review to the supplemental Biologics License Application for satralizumab for MOGAD, marking a potential first-in-class targeted treatment for this rare central nervous ...

Phase 2 IMPACT trial results show that adding certolizumab pegol to standard heparin and aspirin significantly lowers adverse pregnancy outcomes in high-risk antiphospholipid syndrome.

Smartwatches significantly overestimate how many calories people burn during exercise, according to a study published online ...

Stage 1 to 3 CKM syndrome linked to significantly higher mean-mean, mean-maximum carotid intima-medial thickness.

Phase 3 HAELO data showed an 87% reduction in monthly attack rates with Ionvoguran ziclumeran, with a PDUFA target date of March 10, 2027.

Areas under curve were 0.79, 0.78, and 0.86 for hypertension, ischemic heart disease, and cerebrovascular accident, respectively.

Preoperative iron is associated with an improvement in number of days alive and at home in the first 90 days after surgery.